Research Article Volume 01, Issue No. 02. 2025

The Medical Journal of Pulmonology and Respiratory Medicine



Management Of Lung Cancer

[1] Kania, [1] Fiska

[1] Faculty of Medicine, Padjadjaran University, Bandung City, West Java, Indonesia

Correspondence : dokter.kania93847472@gmail.com

Article History :

Received date : 2024/07/23
Revised date : 2024/08/10
Accepted date : 2024/09/14
Published date : 2025/01/18

Copyright: *© 2024 by the authors . Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) License (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: The management of lung cancer has witnessed substantial advancements, necessitating a multidisciplinary approach that integrates various specialties to enhance patient outcomes. The literature reveals critical insights into the importance of timely diagnosis, treatment strategies, and the role of palliative care in managing this complex disease. **Literature Review:** (Kochovska et al., 2020) further contribute to this discussion by exploring the integration of early palliative care in lung cancer management. Their systematic review and meta-analysis reveal mixed evidence regarding the effectiveness of early palliative care interventions, suggesting that while it can enhance symptom management and quality of life, the impact on overall patient outcomes remains uncertain. They advocate for personalized care plans that align with patients' unique needs, emphasizing the importance of integrating palliative care into the treatment trajectory. (Daniel Humberto Pozza & Ramon Bezerra Andrade de Mello, 2022) delve into treatment sequencing strategies, highlighting the significance of predictive biomarkers in tailoring therapies for lung cancer patients. They note advancements in histopathology and molecular diagnostics that have improved survival rates, stressing the necessity for comprehensive initial assessments to determine optimal treatment pathways. This personalized approach is increasingly recognized as vital in effective lung cancer management. (Zarinshenas et al., 2023) address barriers to effective management, particularly in early-stage lung cancer screening and biomarker testing. They identify underutilization of low-dose computed tomography (LDCT) and various challenges that hinder broader implementation of screening programs, which are crucial for early detection and improved outcomes. **Conclusion:** In conclusion, the literature on lung cancer management collectively underscores the necessity of a multidisciplinary approach that incorporates timely diagnosis, personalized treatment strategies, and the integration of palliative care. The advancements in molecular diagnostics and targeted therapies present promising avenues for improving patient outcomes; however, challenges such as screening underutilization and resistance to treatment must be addressed to optimize management strategies further.

Keyword: Management, Lung Cancer

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The management of lung cancer has evolved significantly over recent years, reflecting a growing understanding of the disease's complexity and the necessity of a multidisciplinary approach. The literature highlights various aspects of lung cancer management, from diagnosis and treatment strategies to palliative care and screening methodologies.

In 2016, Denton and Conron examined the role of multidisciplinary healthcare teams in improving outcomes for lung cancer patients. Their study revealed that delays in diagnosis and treatment could be mitigated by a coordinated approach involving multiple specialties (Denton & Conron, 2016). They emphasized the importance of timely interventions, particularly in cases of early-stage non-small cell lung cancer (NSCLC), where the choice of surgical procedure is critical for patient prognosis.

Building on this foundation, Kochovska et al. (Kochovska et al., 2020) conducted a systematic review and meta-analysis focusing on the integration of palliative care in lung cancer management. They found that early referral to palliative care could enhance symptom management and overall quality of life for patients. However, the evidence for the effectiveness of such interventions was mixed, indicating a need for further investigation into the timing and nature of palliative care integration (Kochovska et al., 2020).

In 2022, Pozza and Andrade de Mello discussed treatment sequencing strategies, emphasizing the importance of identifying predictive biomarkers to tailor therapies for lung cancer patients (Daniel Humberto Pozza & Ramon Bezerra Andrade de Mello, 2022). Their review underscored the advancements in histopathology and molecular diagnostics that have improved survival rates, while also highlighting the necessity for a comprehensive initial workup (Daniel Humberto Pozza & Ramon Bezerra Andrade de Mello, 2022). They noted that despite the potential for curative

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

treatment in early-stage cases, many patients require a combination of therapies, including chemotherapy and immunotherapy, which have become standard due to their survival benefits.

Zarinshenas et al. (Zarinshenas et al., 2023) further explored the barriers to effective management, particularly concerning early-stage lung cancer screening and biomarker testing. They highlighted the underutilization of low-dose computed tomography (LDCT) and the challenges that impede broader implementation of screening programs, which are essential for early detection and improved outcomes (Zarinshenas et al., 2023).

Finally, McLaughlin et al. (McLaughlin et al., 2023) provided insights into the advancements in targeted therapies for non-small cell lung cancer. They discussed the evolution of treatment paradigms driven by the understanding of lung cancer as a molecularly heterogeneous disease, which has led to significant improvements in patient outcomes. However, they also pointed out the ongoing need for novel therapeutics to address emerging resistance patterns (McLaughlin et al., 2023).

Together, these articles illustrate a comprehensive landscape of lung cancer management that underscores the importance of a multidisciplinary approach, early detection, and personalized treatment strategies to enhance patient outcomes.

LITERATURE REVIEW

The article "Improving outcomes in lung cancer: the value of the multidisciplinary health care team" by Denton and Conron (Denton & Conron, 2016) provides a comprehensive examination of the critical role that multidisciplinary teams (MDTs) play in the management of lung cancer. The authors highlight the findings of Salomaa et al., which reveal significant delays in the diagnosis and treatment of lung cancer, underscoring the necessity for a collaborative approach to enhance patient outcomes.

One of the central insights of the article is the identification of various factors contributing to diagnostic delays. The authors argue that a multidisciplinary

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

approach can effectively mitigate these delays by ensuring that patients receive timely and accurate diagnoses. The presence of tumor boards is particularly emphasized, as they have been associated with increased rates of radiation therapy for early-stage lung cancer cases that are not candidates for surgery. This suggests that the integration of diverse expertise within MDTs can lead to more informed decision-making and better treatment pathways for patients.

Furthermore, the article discusses the significant variability in treatment decisions influenced by MDTs, with changes in cancer management occurring in 2% to 52% of cases. However, it is also noted that a considerable percentage of cases, ranging from 27% to 52%, resulted in a failure to reach a decision. This highlights the challenges faced by MDTs, including communication barriers and the need for streamlined processes to enhance collaboration among specialists.

The authors stress the importance of obtaining a tissue diagnosis when lung cancer is suspected, as this is crucial for determining the tumor type and guiding subsequent management strategies. This point is particularly relevant given the aggressive nature of lung cancer, where rapid tumor growth can lead to upstaging if treatment is delayed. The article underscores that timely interventions are vital for improving prognosis, especially in cases of non-small cell lung cancer (NSCLC), where selecting the appropriate surgical procedure is paramount.

The article "Earlier multidisciplinary palliative care intervention for people with lung cancer: a systematic review and meta-analysis" by Kochovska et al. (Kochovska et al., 2020) presents a comprehensive examination of the role of early integrated palliative care in the management of lung cancer, a disease that is the leading cause of cancer mortality globally. The authors underscore the significant morbidity associated with lung cancer, which often leads to poorly managed symptoms that adversely affect patients' quality of life. This systematic review aims to assess the current evidence regarding the effectiveness of early palliative care interventions in improving outcomes for patients and their caregivers.

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The authors provide a thorough analysis of the existing literature, highlighting that while palliative care has been shown to enhance symptom control and overall well-being in patients with life-limiting illnesses, the evidence regarding its early integration in lung cancer care remains mixed. This critical evaluation is essential as it reflects the complexities involved in implementing palliative care interventions in oncology settings. The review suggests that although national guidelines advocate for earlier palliative care integration, the actual impact on patient outcomes is not uniformly positive, indicating a need for further research to clarify these findings.

One of the strengths of this article is its systematic approach, which allows for a robust synthesis of data from multiple studies. This methodology enhances the credibility of the findings and provides a clearer picture of the current state of knowledge in this area. However, the mixed evidence presented raises questions about the generalizability of the results and the specific contexts in which early palliative care may be beneficial. The authors acknowledge this limitation, suggesting that factors such as the timing of intervention and the specific palliative care strategies employed could significantly influence outcomes.

Furthermore, the article emphasizes the importance of personalized care plans that consider the unique needs and preferences of lung cancer patients. This patient-centered approach is crucial, as it aligns with the broader goals of palliative care to improve quality of life and support caregivers. The findings advocate for a more nuanced understanding of how and when palliative care should be integrated into the treatment trajectory of lung cancer patients.

The article "Treatment Sequencing Strategies in Lung Cancer" by Pozza and de Mello (Daniel Humberto Pozza & Ramon Bezerra Andrade de Mello, 2022) provides an in-depth analysis of the current landscape of lung cancer management, emphasizing the interplay between early diagnosis, treatment strategies, and advancements in biomarker identification. The authors highlight lung cancer as a

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

significant public health concern due to its high mortality rate, which underscores the necessity for improved management strategies.

One of the key insights from the article is the role of smoking reduction in decreasing lung cancer incidence. This public health initiative is crucial as it directly correlates with lower rates of new lung cancer cases. The authors effectively establish a link between preventive measures and the overall burden of lung cancer, reinforcing the importance of smoking cessation programs in public health policies.

The article also discusses the importance of early diagnosis and the advancements in histopathology and genetics that have transformed therapeutic approaches. The identification of predictive biomarkers, such as ALK fusion oncogenes, ROS1 rearrangements, and EGFR mutations, is pivotal for personalizing treatment plans. The authors argue that these biomarkers not only aid in selecting appropriate therapies but also enhance the likelihood of improved patient outcomes (Daniel Humberto Pozza & Ramon Bezerra Andrade de Mello, 2022). This personalized approach is increasingly becoming the cornerstone of effective lung cancer management.

Moreover, the authors emphasize the necessity of a comprehensive initial workup that includes imaging techniques like computed tomography and magnetic resonance imaging, alongside pathological tests to ascertain tumor subtypes. This thorough assessment is critical for determining the optimal treatment pathway tailored to the patient's specific condition, which aligns with the growing trend towards individualized medicine in oncology.

The article also addresses the treatment modalities available for lung cancer, noting that surgical intervention remains a potentially curative option for early-stage cases. However, it recognizes that most patients present with advanced disease, necessitating a shift towards radiotherapy and chemotherapy. The authors highlight the significance of immunotherapy, particularly PD-1/PD-L1 blockade, as a standard treatment due to its survival benefits and reduced adverse effects compared

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

to traditional therapies. This reflects a broader trend in cancer treatment towards immunotherapeutic strategies, which have shown promising results in various malignancies.

A critical evaluation of the material reveals that while the article provides a comprehensive overview of treatment strategies and advancements in lung cancer management, it could benefit from a more detailed discussion on the challenges faced in implementing these strategies in clinical practice. For instance, the article could explore barriers such as access to biomarker testing, the variability in treatment availability across different healthcare systems, and the need for ongoing education among healthcare providers regarding the latest treatment protocols.

The article "Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer" by Zarinshenas et al. (Zarinshenas et al., 2023) provides a comprehensive overview of the evolving landscape of lung cancer management, emphasizing the significance of early detection and the role of molecular markers. The authors articulate that lung cancer is no longer viewed as a homogenous disease; rather, it is increasingly recognized for its diverse sub-classifications based on genetic and molecular characteristics. This shift underscores the necessity for a multidisciplinary approach to treatment, which is essential for optimizing patient outcomes.

A critical insight from the article is the emphasis on early detection as a pivotal factor influencing lung cancer prognosis. The authors highlight that recent advancements in screening techniques, particularly low-dose computed tomography (LDCT), have demonstrated efficacy in identifying lung cancer at earlier stages. Despite the promising results of LDCT screening programs, the article points out that such modalities are often underutilized. The authors delve into the multifaceted barriers that hinder the broader implementation of LDCT screening. These include logistical challenges, patient awareness, and healthcare provider education, all of which contribute to the disparities in screening uptake.

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

Furthermore, the article evaluates current advancements in diagnosis and biomarker testing, which are critical for the personalized treatment of lung cancer. The integration of molecular testing into clinical practice has the potential to refine treatment strategies and improve patient outcomes. However, the authors argue that the effective application of these advancements is contingent upon overcoming existing barriers in screening and diagnosis.

The article "Targeted therapies in non-small cell lung cancer: present and future" by McLaughlin, Berkman, and Nana-Sinkam (McLaughlin et al., 2023) provides a comprehensive overview of the advancements in the management of non-small cell lung cancer (NSCLC), emphasizing the significance of targeted therapies in enhancing patient outcomes. The authors articulate the pressing reality that lung cancer remains the leading cause of cancer-related mortality in the United States and the second most prevalent cancer diagnosis globally. This context underscores the critical need for innovative treatment approaches.

A key insight from the article is the recognition of lung cancer as a molecularly heterogeneous disease, which has catalyzed the development of mutation-based targeted therapies. The authors detail how this understanding has led to significant improvements in treatment efficacy, particularly through the identification of specific genetic mutations that can be targeted with novel therapeutics. The article outlines the evolution of these therapies over the past two decades, highlighting the integration of immunotherapy, advancements in radiation therapy, and the refinement of minimally invasive surgical techniques as pivotal components of contemporary lung cancer management.

Furthermore, McLaughlin et al. (McLaughlin et al., 2023) critically evaluate the current landscape of targeted therapies, noting that while there have been substantial advancements, challenges remain in addressing emerging patterns of resistance. This aspect is crucial, as the development of resistance to existing therapies can severely limit therapeutic effectiveness and patient survival. The authors advocate for continued research into novel therapeutics that can further

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

personalize lung cancer treatment, suggesting that future directions should focus on overcoming resistance mechanisms and tailoring therapies to individual patient profiles.

CONCLUSION

The management of lung cancer has witnessed substantial advancements, necessitating a multidisciplinary approach that integrates various specialties to enhance patient outcomes. The literature reveals critical insights into the importance of timely diagnosis, treatment strategies, and the role of palliative care in managing this complex disease.

(Denton & Conron, 2016) emphasize the value of multidisciplinary healthcare teams (MDTs) in mitigating delays in diagnosis and treatment, particularly for early-stage non-small cell lung cancer (NSCLC). Their findings indicate that a coordinated approach among specialists can lead to improved decision-making and treatment pathways, thereby enhancing patient prognosis. They highlight the necessity of obtaining a tissue diagnosis promptly to guide subsequent management strategies, underscoring the aggressive nature of lung cancer.

(Kochovska et al., 2020) further contribute to this discussion by exploring the integration of early palliative care in lung cancer management. Their systematic review and meta-analysis reveal mixed evidence regarding the effectiveness of early palliative care interventions, suggesting that while it can enhance symptom management and quality of life, the impact on overall patient outcomes remains uncertain. They advocate for personalized care plans that align with patients' unique needs, emphasizing the importance of integrating palliative care into the treatment trajectory.

(Daniel Humberto Pozza & Ramon Bezerra Andrade de Mello, 2022) delve into treatment sequencing strategies, highlighting the significance of predictive biomarkers in tailoring therapies for lung cancer patients. They note advancements in histopathology and molecular diagnostics that have improved survival rates,

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

stressing the necessity for comprehensive initial assessments to determine optimal treatment pathways. This personalized approach is increasingly recognized as vital in effective lung cancer management.

(Zarinshenas et al., 2023) address barriers to effective management, particularly in early-stage lung cancer screening and biomarker testing. They identify underutilization of low-dose computed tomography (LDCT) and various challenges that hinder broader implementation of screening programs, which are crucial for early detection and improved outcomes. Their insights underscore the need for addressing these barriers to enhance the effectiveness of lung cancer management strategies.

Finally, (McLaughlin et al., 2023) provide a comprehensive overview of targeted therapies for NSCLC, emphasizing the evolution of treatment paradigms driven by the understanding of lung cancer as a molecularly heterogeneous disease. They highlight significant improvements in patient outcomes due to targeted therapies while also acknowledging the ongoing challenges posed by emerging resistance patterns.

In conclusion, the literature on lung cancer management collectively underscores the necessity of a multidisciplinary approach that incorporates timely diagnosis, personalized treatment strategies, and the integration of palliative care. The advancements in molecular diagnostics and targeted therapies present promising avenues for improving patient outcomes; however, challenges such as screening underutilization and resistance to treatment must be addressed to optimize management strategies further.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. Denton, E. & Conron, M., 2016. Improving outcomes in lung cancer: the value of the multidisciplinary health care team. ncbi.nlm.nih.gov
2. Kochovska, S., H. Ferreira, D., Luckett, T., L. Phillips, J., & C. Currow, D., 2020. Earlier multidisciplinary palliative care intervention for people with lung cancer: a systematic review and meta-analysis. ncbi.nlm.nih.gov
3. Daniel Humberto Pozza, undefined & Ramon Bezerra Andrade de Mello, undefined, 2022. Treatment Sequencing Strategies in Lung Cancer. ncbi.nlm.nih.gov
4. Zarinshenas, R., Amini, A., Mambetsariev, I., Abuali, T., Fricke, J., Ladbury, C., & Salgia, R., 2023. Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer. ncbi.nlm.nih.gov
5. McLaughlin, J., Berkman, J., & Nana-Sinkam, P., 2023. Targeted therapies in non-small cell lung cancer: present and future. ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved